USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
HEMCON, INC.
Address:
HEMCON, INC.
10575 SW CASCADE AVE, STE 130
PORTLAND, OR 97223 4363
Phone:
N/A
URL:
N/A
EIN:
931321343
DUNS:
116661344
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $70,000.00 1
STTR Phase I $458,167.00 2

Award List:

Chitosan hemostatic device for laparoscopic applications

Award Year / Program / Phase:
2005 / STTR / Phase I
Award Amount:
$231,982.00
Agency:
HHS
Principal Investigator:
Research Institution:
OREGON MEDICAL LASER CENTER
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Intraoperative bleeding can be a serious problem in parenchymal organ surgery and is generally difficult to manage during laparoscopic procedures. Our long-term goal is to develop a novel internal chitosan hemostatic device that can be deployed… More

Chitosan Endoluminal Hemostatic Dressing

Award Year / Program / Phase:
2009 / STTR / Phase I
Award Amount:
$226,185.00
Agency:
HHS
Principal Investigator:
Research Institution:
PROVIDENCE HEALTH SYSTEM- -BRAIN INST
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): HemCon, Inc. PA-08-051 Chitosan Endoluminal Hemostatic Dressing Project Summary Abstract P.I. - Hua Xie Page 1 Co-PI - Simon McCarthy Abstract The goal of this proposal is to demonstrate Phase I feasibility of a chitosa n endoluminal hemostatic dressing (CEHD)… More

Hemostatic Agent Development

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$70,000.00
Agency / Branch:
DOD / NAVY
Principal Investigator:
Simon McCarthy, Global Head, Research
Abstract:
We will develop a novel hemostatic, antimicrobial, resorbable, nanofiber dressing utilizing proven hemorrhage control technology in combination with novel advanced technologies. The nanofiber dressing will be prepared using scaleable NanospiderT electrospinning technology. Nanofiber Based Dressing… More